Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
456070.KQ
STRONG SELLENCell · Healthcare · South Korea · $63M · Avg Vol: $573K/d
5
StockRankQ
28
V
37
M
19
P/E (TTM)
—
ROE
-42.4%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 5M | 7M | 5M | 3M | -10.6% |
| EPS | -6.29 | -0.54 | -1.14 | -0.98 | — |
| Shares | 9M | 9M | 11M | 11M | +16.6% |
| Debt | 3M | 3M | 3M | 9M | 38.0% |
| Equity | -16M | 25M | 32M | 26M | 1.8% |
| Op CF | -5M | -4M | -7M | -7M | — |
| Inv CF | -10M | 9M | 3M | -3M | — |
| Fin CF | 14M | -618,727 | 15M | 15M | — |
Loading...
PRICE (1M)-42.8%
SMA 50SMA 200
Close
$5.61
RSI (14)
26.6
52W High
$13.79
From 52W High
0.4%
SCORE BREAKDOWN
Quality
28
ROIC
-26.9%24.4
ROE
-42.4%20.0
GP/Assets
-3.6%8.1
Op. Margin
-1576.4%5.5
FCF/Assets
-16.6%20.3
Piotroski
—28.7
Int. Cover
-26.5x17.7
D/E Ratio
0.36x39.0
Current Ratio
9.07x85.1
Value
37
P/E (TTM)
—N/A
EV/EBITDA
-5.0x73.5
P/FCF
—N/A
P/B
2.4x48.2
P/S
21.2x16.6
Div Yield
—N/A
Momentum
19
52W High %
41%13.2
RS 6M
-163%1.8
SMA 50/200
0.92x39.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$63M
P/E (Forward)
—
Gross Margin
-51.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 456070.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 456070.KQ | ENCell(you) | $63M | 5 | STRONG SELL |
| 166480.KQ | CORESTEMCHEMON Inc. | $69M | 9 | STRONG SELL |
| 235980.KQ | MedPacto, Inc. | $80M | 6 | STRONG SELL |
| 011000.KS | GeneOne Life Science, Inc. | $68M | 1 | STRONG SELL |
| 203400.KQ | ABION Inc. | $54M | 2 | STRONG SELL |
| 323990.KQ | Vaxcell-Bio Therapeutics Co., Ltd. | $88M | 2 | STRONG SELL |
| 389030.KQ | GENINUS Inc. | $74M | 14 | STRONG SELL |
| 095700.KQ | Genexine, Inc. | $111M | 7 | STRONG SELL |
| 048530.KQ | iNtRON Biotechnology, Inc. | $53M | 17 | STRONG SELL |
| 321550.KQ | TiumBio Co., Ltd. | $127M | 7 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%